Bryan K. Kee

Texas Medical Center — United States

Medicine · Health Sciences

28h-index2.9kcitations295works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(128), CAR-T cell therapy research(82), Cancer Research and Treatments(74), Genetic factors in colorectal cancer(70), Cancer Genomics and Diagnostics(68)

Publications295 total

Hepatectomy Plus Chemotherapy or Chemotherapy Alone for Resectable Liver and Unresectable Lung Metastases from Colorectal Adenocarcinoma (LUNA): A Randomized Phase II Trial
Annals of Surgical Oncology·2025· 1 cited
Supplementary Figure 11 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplemental Figure 2 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplemental Figure 4 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplemental Figure 3 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplementary Figures and Tables from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplemental Figure 5 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplemental Figure 6 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplemental Figure 9 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplementary Figure 12 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplemental Figure 10 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplemental Figure 7 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplemental Figure 8 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplemental Figure 1 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAF metastatic colorectal cancer
Cancer Cell·2025· 9 citedOpen Access
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT
JCO Precision Oncology·2025· 1 cited
DAILY: A prospective single arm study evaluating the impact of vitamin D, aspirin, exercise, and diet in colorectal cancer patients with ctDNA-defined minimal residual disease.
Journal of Clinical Oncology·2025
Open-label phase Ib/II study of cetuximab (CET) plus LY3214996 with or without abemaciclib in patients (pts) with anti-EGFR-refractory metastatic colorectal cancer (mCRC).
Journal of Clinical Oncology·2025
Clinicopathologic features of complement activation signatures in colorectal cancer.
Journal of Clinical Oncology·2025
BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy
npj Precision Oncology·2025· 1 citedOpen Access
page 1 of 15Next →

Frequent Co-authors

Michael J. Overman(36), Scott Kopetz(36), Van K. Morris(28), Arvind Dasari(21), Kanwal Raghav(19), Cathy Eng(18), Robert A. Wolff(18), Christine M. Parseghian(15), David R. Fogelman(14), Benny Johnson(13), Funda Meric‐Bernstam(13), David S. Hong(12), Eduardo Vilar(11), Siqing Fu(10), Sarina A. Piha‐Paul(10), Apostolia M. Tsimberidou(10), Dipen M. Maru(9), Filip Jankú(8), Imad Shureiqi(8), John Paul Shen(8)